


STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL:

USAN	FORODESINE HYDROCHLORIDE
PRONUNCIATION	fore oh' de seen
THERAPEUTIC CLAIM	Treatment of T-Cell malignancies such as acute lymphoblastic leukemia (ALL) and cutaneous T-cell lymphoma (CTCL)
CHEMICAL NAMES	
1)	4 <i>H</i> -Pyrrolo[3,2- <i>d</i>]pyrimidin-4-one, 7-[(2 <i>S</i> ,3 <i>S</i> ,4 <i>R</i> ,5 <i>R</i>)-3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl]-1,5-dihydro-, monohydrochloride
2)	(-)-7-[(2 <i>S</i> ,3 <i>S</i> ,4 <i>R</i> ,5 <i>R</i>)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]-1,5-dihydro-4 <i>H</i> -pyrrolo[3,2- <i>d</i>]pyrimidin-4-one monohydrochloride

STRUCTURAL FORMULA



MOLECULAR FORMULA	C ₁₁ H ₁₄ N ₄ O ₄ · HCl
MOLECULAR WEIGHT	302.7
TRADEMARK	Unknown as yet
MANUFACTURER	BioCryst Pharmaceuticals
CODE DESIGNATION	BCX-1777
<u>CAS</u> REGISTRY NUMBER	284490-13-7